ReviewPLoS neglected tropical diseases2025
The emerging fungal pathogen Cryptococcus gattii: Epidemiology, pathogenesis, immunomodulatory attributes, and drug susceptibility.
Review in PLoS neglected tropical diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Reactive Oxygen Species-Responsive Signaling Networks and Oxidative Stress Adaptation in Critical Priority Fungal Pathogens.Journal of fungi (Basel, Switzerland) · 2026Review
- Anticryptococcal Evaluation of the Allylimine 3H2: Modulation of Virulence Traits and Synergistic Action with Amphotericin B.ACS omega · 2026Article
- Anti-granulocyte macrophage colony-stimulating factor autoantibodies: A rising cause of infectious diseases.PLoS pathogens · 2026Article
- Article
- Unusual cutaneous manifestations of disseminated Cryptococcus gattii infection in an immunocompetent host.Revista do Instituto de Medicina Tropical de Sao Paulo · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
The emerging fungal pathogen, Cryptococcus gattii, causes infections in both immunocompromised and immunocompetent individuals, often resulting in high mortality rates. While Cryptococcus neoformans is predominantly associated with cryptococcosis in immunocompromised patients, the significance of C. gattii infections has garnered attention due to its prevalence among seemingly healthy individuals. Notably, C. gattii exhibits distinct epidemiological patterns, geographic distribution, genotypes, and phenotypes compared to C. neoformans. However, the comprehension of C. gattii's virulence characteristics, regulatory mechanisms, and therapeutic avenues has lagged behind those of C. neoformans. The less robust clinical and epidemiological data, coupled with the limitations of effective treatment options, underscore the urgency in addressing C. gattii as a serious public health threat. In this review, I discuss the epidemiology, virulence factors, regulatory mechanisms, immunomodulatory attributes, and drug susceptibility of C. gattii. This comprehensive discussion aims to enhance our understanding of this emerging fungal pathogen and potentially contribute to the development of more effective prevention and management strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.